Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 6,771 matching trials from the live ClinicalTrials.gov search.

Filters: Bethesda, Maryland Clear all

Conditions: Membranous Glomerulonephritis, Lupus Membranous Nepropathy
Interventions: Sirolimus; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 13 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depression, Involutional, Major Depresssion
Interventions: Yohimbine hydrochloride, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
Interventions: Crofelemer 125 MG [Mytesi], Placebo; Drug
Lead sponsor: Napo Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 27
States / cities: Prescott, Arizona • Anaheim, California • Corona, California + 24 more

Conditions: Metastatic Breast Cancer
Interventions: LY2523355, ixabepilone, pegfilgrastim, filgrastim; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 12
States / cities: Fort Myers, Florida • Pensacola, Florida • Gainesville, Georgia + 9 more

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lower GI Disease, Gastrointestinal Diseases
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Inherited Hematological Diseases, Rare Diseases, FPDMM
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 1 Day to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2099
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fever, Mycoses, Neutropenia
Interventions: FK463; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Male Factor Infertility, Female Factor Infertility
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
Interventions: Trametinib, Hydroxychloroquine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Daclizumab; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Focal Hand Dystonia
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Corticobasal Syndrome
Interventions: Phoresor II; Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 40 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Moderate to Severe Glabellar Lines
Interventions: Corabotase, Placebo; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 13 more

Conditions: HIV
Interventions: VRC-HIVMAB060-00-AB (VRC01); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic, Cardiovascular Disease, Hyperinsulinemia
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 7 Years to 70 Years
Enrollment: 1,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Skin Cancer, Melanoma, Metastatic Melanoma
Interventions: Aldesleukin, CD8 enriched Young TIL; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Interventions: Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Oxaliplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pancreatectomy; Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 75 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 807
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 515 more

Conditions: HIV Infections
Interventions: Interleukin-2; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sarcoidosis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psoriasis
Interventions: Micellar Paclitaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease, Solid Tumor, Leukemia, Neurofibromatosis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain Disorders, Birth Defects, Craniofacial Differences
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

Rapid Antidepressant Effects of Yohimbine in Major Depression

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

A Study of LY2523355 in Participants With Breast Cancer

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Evaluation of Patients With Gastrointestinal Disease

Longitudinal Studies of Patient With FPDMM

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

The Clinical Study of Sex Chromosome Variants

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

Long-Term Motor Learning in Focal Hand Dystonia

Enhancing Brain Activity With Magnetic Stimulation

Electrical Polarization of the Brain in Corticobasal Syndrome

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2

Study of Eye Tissue for Sarcoidosis

Micellar Paclitaxel to Treat Severe Psoriasis

Validating Pain Scales in Children and Young Adults

Study on Moebius Syndrome and Congenital Facial Weakness Disorders